Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin?

Open access
Baillargeon, Jean-Patrice, Nestler, John E. · 2006 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Polycystic ovary syndrome (PCOS) affects 6–10% of women of child-bearing age (1). It is defined by hyperandrogenism, chronic anovulation, and/or polycystic ovaries (two of three criteria); after exclusion of secondary causes (2). However, it has become apparent that insulin resistance and hyperinsulinemia play a critical role in the syndrome’s pathogenesis (1). Despite advances over the past decade, many questions remain regarding both the nature of insulin resistance in PCOS and the mechanism by which insulin resistance or insulin produces hyperandrogenemia. During the past 15 yr, several studies demonstrated that insulin stimulates ovarian steroidogenesis in vitro. At physiological concentrations, insulin increases androgen production by cultured ovarian cells from women with PCOS (3), an increase significantly greater than that after stimulation of cells from normal women. Moreover, combined stimulation with LH and insulin at physiological concentrations have been shown to synergistically increase androgen biosynthesis by ovarian tissues from normal and PCOS women (4). LH enhances theca cell steroidogenesis mostly through the cAMP-protein kinase A pathway. The molecular mechanism by which insulin regulates steroidogenesis is less well understood, but it has clearly been shown that insulin acts through its own receptor (3). In classical insulin-responsive tissues, insulin’s actions are mediated via three major pathways: the phosphatidyl-inositol 3-kinase (PI-3K) pathway, implicated in the metabolic effects of insulin; the MAPK pathway, responsible for the mitogenic effects of insulin; and the protein kinase C (PKC) pathway, which can also be activated via G protein activation of phospholipase C. Because LH and insulin act physiologically via distinct intracellular signaling mechanisms, their synergistic enhancement of theca cell steroidogenesis likely entails important interactions between pathways of these two respective hormone. Indeed, it has been shown that insulin significantly increases LH-driven cAMP accumulation in theca cells (5). This insulin-stimulated increase in cAMP could be induced through PI-3K and/or PKC (6, 7) but probably not via the MAPK pathway (7). These observations provide a molecular basis to the hypothesis of significant cross talk between the LH and insulin signaling pathways and support the possibility of a defect in women with PCOS affecting both insulin and LH-stimulated ovarian androgen production as well as synergistic responses. Increased ovarian androgen production in women with PCOS, compared with normal women, has also been demonstrated in vivo (8). Both chronic stimulation by LH and insulin have been implicated in this ovarian androgen hyperresponsiveness because most women with PCOS have increased LH and/or insulin levels. To control for chronic stimulation by LH, normal and PCOS women were challenged with human chorionic gonadotropin before and 4 wk after LH suppression with a long-acting analog of GnRH (8). Suppression of LH did not alter the typical exaggerated plasma 17α-hydroxyprogesterone response to human chorionic gonadotropin. Conversely, serum total and non-SHBG-bound testosterone levels decreased significantly after direct suppression of pancreatic insulin release for 10 d with diazoxide in PCOS women (9). Moreover, reduction of insulinemia with acarbose, which slows down intestinal absorption of carbohydrates, also reduced serum testosterone levels in PCOS (10). These studies all underscore the importance of insulin in the pathogenesis of PCOS. Numerous studies have demonstrated that any treatment aimed at improving insulin resistance in women with PCOS results in lower androgen levels and improves ovulatory function (1). The exaggerated steroidogenic response to LH stimulation tests also improved (11, 12), suggesting normalization of ovarian androgen hyperresponsiveness. Finally, we conducted a study using insulin-sensitizing drugs [namely metformin, a biguanine, and rosiglitazone, a peroxisomal proliferator-activated receptor (PPAR)-γ agonist] in nonobese women with PCOS and normal insulin levels (13). The results demonstrated a normalization of serum testosterone levels and ovulation in actively treated groups, compared with placebo. Even if the women were normoinsulinemic at baseline, metformin significantly reduced their insulin levels, but rosiglitazone did not. These findings suggest that some women with PCOS have an increased ovarian sensitivity to insulin without global insulin resistance or hyperinsulinemia. In this case, any reduction in insulin levels (as with metformin) or any direct effect on the ovarian hyperresponsiveness (which may be the case with rosiglitazone) would be beneficial. Rosiglitazone might reduce ovarian androgen hyperresponsiveness through insulin-dependent or insulin-independent mechanisms. Clinical examples of selective defects in the metabolic pathway of insulin action have been reported in pseudoacromegaly (14) and diabe

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-1804

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 169

Metadata

Authors
Baillargeon, J.-P., & Nestler, J. E.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2006-01
Volume
91
Issue
1
Pages
22-24
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1974380188
Cited by
169
References
6
FWCI
13.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin? https://app.cochat.ai/papers/10.1210/jc.2005-1804
The paper
Baillargeon, J.-P., & Nestler, J. E. (2006). Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-1804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.